Taking people in FranceNo phase
Tracks safety and effectiveness of Medtronic products on the market
Follows people treated with Medtronic devices for heart rhythm, brain, bladder and digestive conditions.
Key facts
- Who runs it
- Medtronic
- Where
- Avignon, Bordeaux, Boulogne-Billancourt, Brest, Caen, Chambray, Clermont-Ferrand, Créteil, Dijon, La Rochelle, La Tronche, Lille, Marseille, Montpellier, Nantes, Ollioules, Paris, Pessac, Pringy, Rennes, Rouen, Saint-Priest-en-Jarez, Strasbourg, Toulouse, and Villeurbanne, FranceSee the 25 sitesAlso in 40 other countries, 370 sites
- Trial code
- Registry title
- Product Surveillance Registry
- Status
- Recruiting
- People taking part
- 100,000 people, planned
- Started
- Jan 2012
- Expected to end
- Jan 2040
- Type of study
- Observational
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who have, or are about to receive, a Medtronic product that is already on the market, to follow its safety and performance.
- Sex
- All sexes can join.
- Earlier treatment
- The person has been treated with, or is going to be treated with, a Medtronic product that is allowed in this registry. They must be within the enrollment window around the start of therapy, or meet the rules for joining later.
Main reasons for not taking part
- People who cannot be reached for follow-up
- People who meet exclusion rules set by local law
- People already in, or planning to join, another drug or device study that could affect the results
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
- Patient has or is intended to receive or be treated with an eligible Medtronic product
- Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment
Who cannot take part
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
- Patient who is, or will be, inaccessible for follow-up
- Patient with exclusion criteria required by local law
Where in France
Also in 40 other countries, 370 sites
- AvignonHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- BordeauxHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- Boulogne-BillancourtHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- BrestHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- CaenHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- ChambrayHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- Clermont-FerrandHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- CréteilHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- DijonHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- La RochelleHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- La TroncheHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- LilleHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- MarseilleHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- MontpellierHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- NantesHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- OllioulesHospital not named in the registryContact: Medtronic Product Surveillance RegistryNo longer taking part
- ParisHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- PessacHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- PringyHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- RennesHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- RouenHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- Saint-Priest-en-JarezHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- StrasbourgHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- ToulouseHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
- VilleurbanneHospital not named in the registryContact: Medtronic Product Surveillance RegistryTaking people
About the trial
What the trial wants to find out
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Medtronic Product Surveillance Registry
- Plain-language title
- Tracks safety and effectiveness of Medtronic products on the marketGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 October 2026